Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021
May 07 2021 - 7:30AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that the Company will release its
first quarter 2021 financial results before the open of
the U.S. financial markets on Friday, May 14, 2021.
Management will host a conference call at 8:30 a.m.
ET that day to discuss the Company’s financial results and
provide an update on its business.
To register for the conference call please use this link:
https://www.incommglobalevents.com/registration/client/7304/iterum-therapeutics-1st-quarter-2021-financial-results-conference-call/.
After registering, a confirmation email will be sent,
including dial-in details and a unique code for entry. The Company
recommends registering at minimum ten minutes prior to the start of
the call. Following the conference call, a replay will be
available at
https://www.incommglobalevents.com/replay/5793/iterum-therapeutics-1st-quarter-2021-financial-results-conference-call/Replay
Access Code: 768632
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside the Company’s
control, including the uncertainties inherent in the initiation and
conduct of clinical trials, availability and timing of
data from clinical trials, changes in regulatory requirements or
decisions of regulatory authorities, the timing of approval of any
submission, changes in public policy or legislation,
commercialization plans and timelines, if oral sulopenem is
approved, the actions of third-party clinical research
organizations, suppliers and manufacturers, risks regarding
intellectual property rights in product candidates and the ability
to defend and enforce any such intellectual property rights, the
accuracy of the Company’s expectations regarding how far into the
future the Company’s cash on hand will fund the Company’s ongoing
operations, the impact of COVID-19 and related responsive measures
thereto, the outcome, impact, effects and results of the Company’s
evaluation of corporate, strategic, financial and financing
alternatives, including the terms, timing, structure, value,
benefits and costs of any corporate, strategic, financial or
financing alternative and the Company’s ability to complete one at
all and other factors discussed under the caption “Risk Factors” in
its most recently filed Annual Report on Form 10-K, and other
documents filed with the SEC from time to time. Forward-looking
statements represent the Company’s beliefs and assumptions only as
of the date of this press release. Except as required by law, the
Company assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Investor Contact:Judy
MatthewsChief Financial Officer
312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024